Comparison
Pramlintid vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
151126-32-8
2179963-22-7
Molecular weight
3949.4 g/mol
4727 g/mol
Half-life
no data
168 h
Sequence
no data
modifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
Pramlintid
Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
0
4
of which in humans
0
4
Effects recorded
2
3
Open conflicts
1
1
Documented adverse events
2
2
Legal status
Full entries
Frequently asked questions
- What is the difference between Pramlintid and Survodutide?
- Pramlintid is classified as "Metabolic", while Survodutide is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Pramlintid or Survodutide?
- The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Pramlintid and Survodutide in Germany and the United States?
- Germany: Pramlintid — Unapproved, Survodutide — Unapproved. United States: Pramlintid — Prescription, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.